Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
24 stopped studies mapped to Lung Squamous Cell Carcinoma and descendants · 92% state a reason
Over the 24 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung… | Phase 1 | terminated | Dec 15, 2022 | Mythic Therapeutics | Business decision | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by… | Phase 2 | withdrawn | Jun 26, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | Phase 2 | withdrawn | Jun 29, 2021 | University of British Columbia | Overestimated pool of eligible patients and the potential participants either declined… | Other (stated, no rule matched) |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | Phase 2 | terminated | Feb 4, 2019 | Lung Cancer Group Cologne | Study-related difficulties faced with patient enrolment, no safety-related reasons | Safety / toxicity |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care… | Phase 2 | withdrawn | Feb 13, 2020 | SWOG Cancer Research Network | The pharmaceutical company sold the compound and pulled out. | Sponsor / business decision |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous… | Phase 1 | withdrawn | Jun 28, 2011 | Mayo Clinic | lack of access to study drug | Other (stated, no rule matched) |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | Phase 1 / Phase 2 | terminated | Mar 21, 2016 | PrECOG, LLC. | Company discontinued further development of study drug for this indication | Sponsor / business decision |
| NCT00784329 | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway… | N/A | withdrawn | Nov 3, 2008 | Lahey Clinic | not stated | Not stated |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | Phase 2 / Phase 3 | withdrawn | Nov 17, 2017 | University College, London | drug no longer available | Other (stated, no rule matched) |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 / Phase 2 | withdrawn | Sep 1, 2015 | Erin Bertino | PI decision due to funding support | Funding |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients… | Phase 1 | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | Due to no accrual. | Enrollment / accrual |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | Phase 2 | terminated | Dec 14, 2011 | Dana-Farber Cancer Institute | Safety issues/concerns per DF/HCC PI | Safety / toxicity |
| NCT00042835 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on… | Phase 1 | suspended | May 28, 2009 | Envita Medical Center, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials